[go: up one dir, main page]

PA8581401A1 - Compuestos de imedazopiridina como agonistas del receptor 5-ht4 - Google Patents

Compuestos de imedazopiridina como agonistas del receptor 5-ht4

Info

Publication number
PA8581401A1
PA8581401A1 PA20038581401A PA8581401A PA8581401A1 PA 8581401 A1 PA8581401 A1 PA 8581401A1 PA 20038581401 A PA20038581401 A PA 20038581401A PA 8581401 A PA8581401 A PA 8581401A PA 8581401 A1 PA8581401 A1 PA 8581401A1
Authority
PA
Panama
Prior art keywords
group
rent
carbon atoms
compounds
ramified
Prior art date
Application number
PA20038581401A
Other languages
English (en)
Inventor
Yasuhiro Katsu
Hirohide Noguchi
Satoru Iguchi
Kana Kon-I
Chikara Uchida
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PA8581401A1 publication Critical patent/PA8581401A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

ESTA INVENCION PROPORCIONA UN COMPUESTO DE FORMULA (I): EN LA QUE R1 REPRESENTA UN ATOMO DE HIDROGENO O UN ATOMO DE HALOGENO; R2 REPRESENTA UN GRUPO METILO O UN GRUPO ETILO; R3 REPRESENTA UN GRUPO ALQUILO RAMIFICADO QUE TIENE DE 3 A 6 ATOMOS DE CARBONO O UN GRUPO ALQUILO QUE TIENE DE 3 A 6 ATOMOS DE CARBONO SUSTITUIDOS POR UN GRUPO ALCOXI QUE TIENE DE 1 A O ATOMOS DE CARBONO; CON LA CONDICION DE QUE CUANDO EL ATOMO DE CARBONO TERMINAL DE DICHO GRUPO ALQUILO SE SUSTITUYA POR DICHO GRUPO ALCOXI, DICHO GRUPO ALQUILO ES UN GRUPO ALQUILO RAMIFICADO; Y SALES FARMACEUTICAMENTE ACEPTABLES DEL MISMO. ESTOS COMPUESTOS TIENEN ACTIVIDAD DE UNION AL RECEPTOR 5-HT4, Y DE ESTA FORMA SON UTILES PARA EL TRATAMIENTO DE LA ENFERMEDAD DE REFLUJO ESOFAGICO, DISPEPSIA NO ULCEROSA, DISPEPSIA FUNCIONAL, SINDROME DEL INTESTINO IRRITABLE O SIMILARES EN MAMIFEROS, ESPECIALMENTE EN HUMANOS. ESTA INVENCION TAMBIEN PROPORCIONA UNA COMPOSICION FARMACEUTICA QUE COMPRENDE EL COMPUESTO ANTERIOR.
PA20038581401A 2002-09-20 2003-09-02 Compuestos de imedazopiridina como agonistas del receptor 5-ht4 PA8581401A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41248502P 2002-09-20 2002-09-20

Publications (1)

Publication Number Publication Date
PA8581401A1 true PA8581401A1 (es) 2004-05-26

Family

ID=32030883

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20038581401A PA8581401A1 (es) 2002-09-20 2003-09-02 Compuestos de imedazopiridina como agonistas del receptor 5-ht4

Country Status (13)

Country Link
US (1) US7012080B2 (es)
EP (1) EP1543005A1 (es)
JP (1) JP2006502181A (es)
AR (1) AR041302A1 (es)
AU (1) AU2003263424A1 (es)
BR (1) BR0314284A (es)
CA (1) CA2497665A1 (es)
DO (1) DOP2003000703A (es)
GT (1) GT200300207A (es)
MX (1) MXPA05001882A (es)
PA (1) PA8581401A1 (es)
TW (1) TW200424198A (es)
WO (1) WO2004026869A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
EP1620435A1 (en) * 2003-04-21 2006-02-01 Pfizer Inc. IMADAZOPYRIDINE COMPOUNDS HAVING 5-HT sb 4 /sb RECEPTOR AGONISTIC ACTIVITY AND 5-HT sb 3 /sb RECEPTOR ANTAGONISTIC ACTIVITY
TW200533348A (en) * 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7615648B2 (en) * 2004-06-01 2009-11-10 Eli Lilly And Company Aminomethyl-azacycle derivatives as inhibitors of monoamine uptake
CA2569654C (en) * 2004-06-15 2010-12-21 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
US7737163B2 (en) * 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
ES2332808T3 (es) * 2004-11-05 2010-02-12 Theravance, Inc. Compuestos agonistas del receptor 5-ht4.
US7396933B2 (en) * 2004-11-05 2008-07-08 Theravance, Inc. Quinolinone-carboxamide compounds
MX2007007818A (es) * 2004-12-22 2007-09-11 Theravance Inc Compuestos de indazol-carboxamida.
ES2366375T3 (es) * 2005-02-22 2011-10-19 Pfizer, Inc. Derivados de oxiindol, como agonistas del receptor 5-ht4.
CN101163701A (zh) * 2005-03-02 2008-04-16 施万制药 作为5-ht4受体激动剂的喹啉酮化合物
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
CN102753527B (zh) 2010-02-02 2014-12-24 诺华股份有限公司 用作crf受体拮抗剂的环己基酰胺衍生物
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
EA201491990A1 (ru) 2012-05-03 2015-02-27 Новартис Аг L-малатная соль 2,7-диазаспиро[4.5]дец-7-иловых производных и их кристаллические формы в качестве агонистов грелиновых рецепторов
EP3215509B1 (en) 2014-11-06 2020-02-26 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
SMT202400187T1 (it) 2014-11-06 2024-07-09 Bial R&D Investments S A Pirazolo(1,5-a)pirimidine sostituite e loro utilizzo nel trattamento di disturbi medici
ES2958391T3 (es) 2014-11-06 2024-02-08 Bial R&D Invest S A Imidazo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos
AU2017246455B2 (en) 2016-04-06 2021-09-30 Bial - R&D Investments, S.A. Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
US10787454B2 (en) 2016-04-06 2020-09-29 BIAL—BioTech Investments, Inc. Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
WO2017176962A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics, Inc. Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
US11345698B2 (en) 2016-05-05 2022-05-31 Bial—R&D Investments, S.A. Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders
BR112018072552A8 (pt) 2016-05-05 2023-03-14 Lysosomal Therapeutics Inc Compostos de imidazo [1,2-b]piridazinas e imidazo [1,5-b] piridazinas substituídas, composição farmacêutica que os compreende e seu uso no tratamento de distúrbios médicos

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851423A (en) 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
JP2643274B2 (ja) 1988-04-08 1997-08-20 三菱化学株式会社 イミダゾ〔１，２−ａ〕ピリジン誘導体
US5196547A (en) * 1991-03-07 1993-03-23 G. D. Searle & Co. Meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5137893A (en) * 1991-03-07 1992-08-11 G. D. Searle & Co. Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5219850A (en) * 1991-03-07 1993-06-15 G. D. Searle & Co. Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5260303A (en) * 1991-03-07 1993-11-09 G. D. Searle & Co. Imidazopyridines as serotonergic 5-HT3 antagonists
GB9221468D0 (en) * 1992-10-13 1992-11-25 Smithkline Beecham Plc Pharmaceuticals
ZA948393B (en) * 1993-11-01 1995-06-26 Polartechnics Ltd Method and apparatus for tissue type recognition
AU3192295A (en) * 1994-08-11 1996-03-07 Yamanouchi Pharmaceutical Co., Ltd. Substituted amine derivative and medicinal composition containing the same
US5807272A (en) * 1995-10-31 1998-09-15 Worcester Polytechnic Institute Impedance spectroscopy system for ischemia monitoring and detection
US6066738A (en) 1996-01-30 2000-05-23 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2249601A1 (en) 1996-04-03 1997-10-23 Thorsten E. Fisher Inhibitors of farnesyl-protein transferase
AU6262698A (en) * 1997-02-04 1998-08-25 National Aeronautics And Space Administration - Nasa Multimodality instrument for tissue characterization
US6026323A (en) * 1997-03-20 2000-02-15 Polartechnics Limited Tissue diagnostic system
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
RU2230740C2 (ru) 1998-03-31 2004-06-20 Акадиа Фармасьютикалз, Инк. Производные азотсодержащих гетероциклических соединений и фармацевтическая композиция на их основе
JP4032566B2 (ja) 1999-06-21 2008-01-16 東レ株式会社 発光素子
CA2461159A1 (en) * 2001-10-22 2003-05-01 Pfizer Inc. Imidazopyridine compounds as 5-ht4 receptor modulators
US6624162B2 (en) * 2001-10-22 2003-09-23 Pfizer Inc. Imidazopyridine compounds as 5-HT4 receptor modulators

Also Published As

Publication number Publication date
MXPA05001882A (es) 2005-06-03
WO2004026869A1 (en) 2004-04-01
AU2003263424A1 (en) 2004-04-08
EP1543005A1 (en) 2005-06-22
JP2006502181A (ja) 2006-01-19
GT200300207A (es) 2004-04-29
US7012080B2 (en) 2006-03-14
BR0314284A (pt) 2005-07-26
AR041302A1 (es) 2005-05-11
DOP2003000703A (es) 2004-03-31
TW200424198A (en) 2004-11-16
US20040122043A1 (en) 2004-06-24
CA2497665A1 (en) 2004-04-01

Similar Documents

Publication Publication Date Title
PA8581401A1 (es) Compuestos de imedazopiridina como agonistas del receptor 5-ht4
PA8582901A1 (es) Compuestos de piperidinil-imidazopiridina n- sustituidos como moduladores del receptor 5 ht4
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
TW200505903A (en) CGRP receptor antagonists
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
MXPA05011710A (es) Derivados de pirimidina con actividad de crf.
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
ECSP055935A (es) Medicamento para la profilaxis y el tratamiento de arteriosclerosis e hipertension
PA8610801A1 (es) Compuestos de aril o heteroaril amida
MA29926B1 (fr) Derives de pyrazine
EA200100971A1 (ru) Новые соединения и композиции в качестве ингибиторов протеазы
ATE466860T1 (de) Cgrp-rezeptorantagonisten
EA200600190A1 (ru) Производные пиримидин-2,4-диона в качестве антагонистов рецептора гонадотропин-высвобождающего гормона
PE20061297A1 (es) Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c
SV2006002103A (es) Compuestos de aril- o heteroarilamida ortosustituidos ref. pc32242a
PA8556801A1 (es) Compuestos de imidazopiridin como moduladores de receptor 5-ht 4
PE20050142A1 (es) 2-hidroxi-3-diaminoalcanos de benzamida
DE602004012858D1 (de) 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
PE20060627A1 (es) Derivados de pirazol condensado como agonistas de los receptores cannabinoides cb1 y/o cb2
EA200300527A1 (ru) Новые способы лечения синдрома "усталых ног"
PE20050420A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
PE20060736A1 (es) DERIVADOS DE PIRROL COMO ANTAGONISTAS DE CRTh2
AR039190A1 (es) Derivados de benzofurano, composicion farmaceutica y medicamento que comprende el compuesto
GT200100148A (es) Derivados de 4-fenil-piridina.
PE20100093A1 (es) Derivados de acetileno